Interaction between warfarin and Panax ginseng in ischemic stroke patients

Journal of Alternative and Complementary Medicine

Volumn 14, Issue 6, 2008, Pages 715-721

  Lee, Sang Hun ^a   Ahn, Young Min ^a   Ahn, Se Young ^a   Doo, Ho Kyung ^a   Lee, Byung Cheol ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GINSENG EXTRACT; UNCLASSIFIED DRUG; WARFAR; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG HALF LIFE; FEMALE; GINSENG; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIGESTION; INTERNATIONAL NORMALIZED RATIO; KOREA; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

AGED; ANTICOAGULANTS; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANAX; WARFARIN;

EID: 49249126098     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2007.0799     Document Type: Article

References (30)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337-344.
2. Jong-Ku P, Jun-Sang Y, Kwang-Woo K, et al. The combined treatment with oriental herbal medicine and Western biomedical medicine among cerebrovascular attack patients. J Korean Oriental Med 2006;27:1-10.
3. Eun-Ju K, Sang-Ho L, Lee-Dong K, et al. Influence of herbal medicine coadministration on the INR in stroke patients taking warfarin. J Korean Oriental Med 2004;25:165-172.
4. Wittkowsky AK. Drug interactions update: Drugs, herbs, and oral anticoagulation. J Thromb Thrombolysis 2001;12:67-71.
5. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355:134-138.
6. Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost 2005;93:3-7.
7. Fugh-Berman A, Ernst E. Herb-drug interactions: Review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-595.
8. Ginsberg JS, Bates SM, Oczkowski W, et al. Low-dose warfarin in rehabilitating stroke survivors. Thromb Res 2002;107:287-290.
9. Radad K, Gille G, Liu L, Rausch WD. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci 2006;100:175-186.
10. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005;45:127-132.
11. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-1106.
12. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-216.
13. Kimura Y, Okuda H, Arichi S. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J Pharm Pharmacol 1988;40:838-843.
14. Park HJ, Lee JH, Song YB, Park KH. Effects of dietary supplementation of lipophilic fraction from Panax ginseng on cGMP and cAMP in rat platelets and on blood coagulation. Biol Pharm Bull 1996;19:1434-1439.
15. Zhu M, Chan KW, Ng LS, et al. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999;51:175-180.
16. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997;54:692-693.
17. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-599.
18. Wei G, Dey L, et al. Brief communication. American ginseng reduces warfarin's effect in healthy patients: A randomized, controlled trial. Ann Intern Med 2004;141:23-27.
19. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108:231S-241S.
20. Erban S. Initiation of warfarin therapy: Recommendations and clinical pearls. J Thromb Thrombolysis 1999;7:145-148.
21. Mohr JP, Thompson JL, Lazar RM, et al. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
22. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.
23. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 1997;54:1195-1203.
24. Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-209.
25. Yun TK. Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 2001;16:53-55.
26. Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician 2003;68:1539-1542.
27. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006;78:2105-2115.
28. Kamali F, Khan TI, King BP, et al. Contribution of age, body size and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004;75:204-212.
29. Linder MW, Looney S, Adams JE, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002;14:227-232.
30. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21:235-242.